The Rogosin Institute (RI) was established in 1983 as an independent, not-for-profit institution for research, treatment and education in kidney disease (including dialysis and transplantation) and cardiovascular disease (secondary to cholesterol and other lipid disorders). The Rogosin Institute also has research programs in polycystic kidney disease, hypertension, endotoxemia, cancer of the kidney and diabetes. The Rogosin Institute is affiliated with New York Presbyterian Hospital-Weill Cornell Medical College and is a corporate member of New York Presbyterian Healthcare network. Rogosin Institute members are on the staff of New York Presbyterian Hospital and have appointments at Weill Cornell Medical College. Several are also on the adjunct faculty at The Rockefeller University.

The Rogosin Institute has been involved in clinical research since it’s inception in 1983. Phase I – IV studies, as well as investigator initiated studies, are conducted. Our therapeutic interests and clinical trial experience with more than 50 pharmaceutical companies and Contract Research Organizations include:

• End Stage Renal Disease (ESRD) involving subjects who are on hemodialysis, peritoneal dialysis or nocturnal hemodialysis.
• Polycystic Kidney Disease
• Chronic Renal Insufficiency involving subjects who are pre-dialysis
• Hypertension; primary and secondary (to renal disease)
• Transplantation (Kidney and Kidney/Pancreas)
• Coronary artery disease
• Hypercholesterolemia
• Hypertriglyceridemia
• Syndrome X
• Low HDL

The Rogosin Institute has clinical facilities in Manhattan at New York Presbyterian Hospital-Weill Cornel Medical College as well as in Queens and Brooklyn. The Rogosin Institute offers both outpatient facilities and inpatient facilities. Research facilities are also located in Xenia, Ohio.

RI outpatient facilities include:

Jack J. Dreyfus Clinic, an outpatient facility for the prevention and treatment of renal (kidney) disease.

Susan R. Knafel Polycystic Disease Center, located within the Jack J. Dreyfus Clinic, to diagnose, and to prevent and treat complications related to polycystic kidney disease.

Hemodialysis Centers located in Manhattan, Queens and Brooklyn.

David D. Thompson Transplantation Centerfor kidney transplants as well as simultaneous pancreas-kidney transplants.

Maurice R. Greenberg Comprehensive Lipid Control Center for prevention and treatment of atherosclerosis and its risk factors for adults and children.

The Rogosin Institute Iris and B. Gerald Cantor Clinical Laboratory, provides general and specialized laboratory tests in all areas.

RI inpatient facilities in New York Presbyterian Hospital-Weill Cornell Medical College include:

The Rogosin Institute Wingfor patients requiring hospitalization for kidney disease related problems and kidney transplantation.

The Rogosin Institute Ralph J. Bunch Dialysis and Apheresis Center for patients undergoing intensive care hemodialysis or LDL-apheresis, which is a specialized treatment for severe genetic hypercholesterolemia.

Clinical and Translational Centers
The Rogosin Institute has access to both New York Presbyterian Hospital-Weill Cornell Medical College Clinical and Translational Science Center and The Rockefeller University Center for Clinical and Translational Science for inpatient studies.

The investigators at The Rogosin Institute include 20 physicians (two with Ph.D. degrees), two Ph.D’s. The Clinical Research Program offers five full time clinical research coordinators, including a Clinical Research Manager, two research nurse practitioners and two part time clinical research assistants.

Albert L. Rubin, M.D.
Area of Expertise: Nephrology/Lipids/Diabetes/Oncology.
Dr. Rubin is the President, Chief Executive Officer and Director of The Rogosin Institute. Dr. Rubin is a Professor of Medicine, Surgery and Biochemistry at Weill Cornell Medical College and an Attending Physician and Surgeon at New York Presbyterian Hospital.

Kurt H. Stenzel, M.D.
Area of Expertise: Nephrology/Oncology.
Dr. Stenzel is the Medical Director, Executive Vice President and Treasurer of The Rogosin Institute. Dr. Stenzel is a Professor of Medicine, Surgery, and Biochemistry at Weill Cornell Medical College and an Attending Physician at New York Presbyterian Hospital. Dr. Stenzel is responsible for research related to renal disease.

Bruce R. Gordon, M.D.
Area of Expertise: Lipids/Atherosclerosis.
Dr. Gordon is the Director of the Clinical Research Program, Chief Operating Officer of The Rogosin Institute and Co-Director of The Rogosin Institute’s Maurice R. Greenberg Comprehensive Lipid Control Center. Dr. Gordon is a Professor of Clinical Medicine and Surgery at Weill Cornell Medical College and an Attending Physician at New York Presbyterian Hospital. Dr. Gordon has the overall responsibility of the Clinical Research Program and has been conducting clinical research for more than 25 years. His research focuses primarily on lipids and cardiovascular research at The Comprehensive Lipid Control Center.

Betty-Jane Sloan, BS, MA,
Certified Clinical Research Coordinator (CCRC)
Ms. Sloan has 18 years experience in clinical research at The Rogosin Institute and is the Research Manager for the Clinical Research Program. Ms. Sloan is a Staff Associate in the Department of Medicine at Weill Cornell Medical College.

Jon Blumenfeld, M.D.
Area of Expertise: Polycystic Kidney Disease/Nephrology/Hypertension

Roxana Bologa, M.D.
Area of Expertise: Nephrology

Jhoong Cheigh, M.D.
Area of Expertise: Nephrology/Transplantation

James Chevalier, M.D.
Area of Expertise: Nephrology

Darshana Dadhania, M.D.
Area of Expertise: Nephrology/Transplantation

Lisa Hudgins, M.D.
Area of Expertise: Lipids/Pediatric Lipids

Jun B. Lee, M.D.
Area of Expertise: Nephrology

Daniel Levine, Ph.D.
Area of Expertise: Lipids/Biochemistry

Frank Liu, M.D.
Area of Expertise: Nephrology

Jonathan Lorch, M.D.
Area of Expertise: Nephrology

Thomas Parker, Ph.D.
Area of Expertise: Lipids/Biochemistry

Alan Perlman, M.D.
Area of Expertise: Nephrology

Robert Riggio, M.D.
Area of Expertise: Nephrology/Transplantation

Stuart Saal, M.D.
Area of Expertise: Nephrology/Transplantation/Lipids

David Serur, M.D.
Area of Expertise: Nephrology/Transplantation

Jeffrey Silberzweig, M.D.
Area of Expertise: Nephrology

Barry Smith, M.D., Ph.D.
Area of Expertise: Diabetes/Oncology

John Sullivan, M.D.
Area of Expertise: Nephrology

John Wang, M.D., Ph.D.
Area of Expertise: Nephrology

The Rogosin Institute employs a highly trained staff of more than 150 professionals including nurse practitioners, registered nurses, social workers, dialysis technicians, phlebotomy technicians, clinical research staff and registered dietitians.

The Rogosin Institute’s patient facilities are located in New York City. Patients mainly come from the greater New York and tri-state area, which is populated with approximately 20,000,000 people. The Rogosin Institute has access to many diverse nationalities and ages.

Institutional Review Boards
The Rogosin Institute can conduct clinical research studies using either central (commercial) Institutional Review Boards (IRB) or the local IRB of the Weill Cornell Medical College or Rockefeller University.

Information Technology
The Rogosin Institute employees a fulltime Database Systems Manager to provide our investigators with data management for investigator initiated studies.

MIQS Disease Manager Plus, a computerized medical informational network system, is utilized at The Rogosin Institute. MIQS provides enhancement of record keeping as well as immediate access to information on a patient’s history, treatment and laboratory data at all Rogosin Institute facilities and New York Presbyterian Hospital-Weill Cornell Medical Cornell.

CenterWatch is listing the following trials that are actively recruiting patients at this center.

• A phase II study to assess the clinical benefit and safety of droxidopa in patients with intradialytic hypotension
• Are You Concerned About Your Cholesterol?
• Autosomal Dominant Polycystic Kidney Disease Registry. Male/female 18 years of age or older, diagnosed with ADPKD.
• Evaluation of the mechanisms causing high blood pressure in people with Autosomal Dominant Polycystic Kidney Disease. Male/female at least 18 years of age who have been diagnosed with ADPKD.
• The Rogosin Institute is offering a lipid screen to those individuals who are interested in participating in clinical research studies but who do not know their cholesterol levels.

For more information, please contact:

Betty-Jane Sloan, M.A., CCRC
Clinical Research Manager
The Rogosin Institute
1167 York Avenue
New York, NY 10021 USA
Phone: 212 702-9600 (ext. 22)
Fax: 212 702-9588
E-mail:

If you are interested in contacting this center to discuss placing a clinical trial there, please complete and send the E-mail form below. A representative from the research center will then follow up with you.

Name:
Address:
City:
State:
Zip:
Phone:
Email address:
Message:

Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

Last updated on August 21, 2008